Lopressor/adverse reactions: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Metoprolol tartrate#Adverse Reactions]]
{{Metoprolol}}
{{CMG}}
 
===Hypertension and Angina===
 
Most adverse effects have been mild and transient.
 
'''Central Nervous System''': [[Tiredness]] and [[dizziness]] have occurred in about 10 of 100 patients. [[Depression]] has been reported in about 5 of 100 patients. Mental [[confusion]] and short-term [[memory loss]] have been reported. [[Headache]], [[nightmares]], and [[insomnia]] have also been reported.
 
'''Cardiovascular''': [[Shortness of breath]] and [[bradycardia]] have occurred in approximately 3 of 100 patients. Cold extremities; [[arterial insufficiency]], usually of the [[Raynaud phenomenon|Raynaud]] type; [[palpitations]]; [[congestive heart failure]]; [[peripheral edema]]; and [[hypotension]] have been reported in about 1 of 100 patients. [[Gangrene]]in patients with pre-existing severe peripheral circulatory disorders has also been reported very rarely. ''(See [[Lopressor contraindications|Contraindications]], [[Lopressor warnings and precautions#warnings|Warnings]], and [[Lopressor warnings and precautions#Precautions|Precautions]])''
 
'''Respiratory''': [[Wheezing]] ([[bronchospasm]]) and [[dyspnea]] have been reported in about 1 of 100 patients (see WARNINGS). [[Rhinitis]] has also been reported.
 
'''Gastrointestinal''': [[Diarrhea]] has occurred in about 5 of 100 patients. [[Nausea]], [[dry mouth]], [[gastric pain]], [[constipation]], [[flatulence]], and [[heartburn]] have been reported in about 1 of 100 patients. [[Vomiting]] was a common occurrence. Postmarketing experience reveals very rare reports of [[hepatitis]], [[jaundice]] and non-specific hepatic dysfunction. Isolated cases of [[transaminase]], [[alkaline phosphatase]], and [[lactic dehydrogenase]] elevations have also been reported.
 
'''Hypersensitive Reactions''': [[Pruritus]] or [[rash]] have occurred in about 5 of 100 patients. Very rarely, [[photosensitivity]] and worsening of [[psoriasis]] has been reported.
 
'''Miscellaneous''': [[Peyronie’s disease]] has been reported in fewer than 1 of 100,000 patients. Musculoskeletal pain, [[blurred vision]], and [[tinnitus]] have also been reported.
 
There have been rare reports of reversible [[alopecia]], [[agranulocytosis]], and [[dry eyes]]. Discontinuation of the drug should be considered if any such reaction is not otherwise explicable.
 
There have been very rare reports of weight gain, [[arthritis]], and [[retroperitoneal fibrosis]] (relationship to Lopressor has not been definitely established).
 
The [[oculomucocutaneous syndrome]] associated with the [[beta blocker]] [[practolol]] has not been reported with Lopressor.
 
===Myocardial Infarction===
 
'''Central Nervous System''': [[Tiredness]] has been reported in about 1 of 100 patients. [[Vertigo]], [[sleep disturbance]]s, [[hallucinations]], [[headache]], [[dizziness]], [[visual disturbance]]s, [[confusion]], and [[reduced libido]] have also been reported, but a drug relationship is not clear.
 
'''Cardiovascular''': In the randomized comparison of Lopressor and placebo described in the CLINICAL PHARMACOLOGY section, the following adverse reactions were reported:
 
{|
| [[File:Metop002.png|800px|thumb]]
|}
 
'''Respiratory''': [[Dyspnea]] of pulmonary origin has been reported in fewer than 1 of 100 patients.
 
'''Gastrointestinal''': [[Nausea]] and [[abdominal pain]] have been reported in fewer than 1 of 100 patients.
 
'''Dermatologic''': [[Rash]] and worsened [[psoriasis]] have been reported, but a drug relationship is not clear.
 
'''Miscellaneous''': Unstable [[diabetes]] and [[claudication]] have been reported, but a drug relationship is not clear.
 
===Potential Adverse Reactions===
 
A variety of adverse reactions not listed above have been reported with other [[beta-adrenergic blocking agents]] and should be considered potential adverse reactions to Lopressor.
 
'''Central Nervous System''': Reversible mental [[depression]] progressing to [[catatonia]]; an acute reversible syndrome characterized by [[disorientation]] for time and place, short-term [[memory loss]], [[emotional lability]], slightly [[clouded sensorium]], and decreased performance on neuropsychometrics.
 
'''Cardiovascular''': Intensification of [[AV block]] (see CONTRAINDICATIONS).
 
'''Hematologic''': [[Agranulocytosis]], nonthrombocytopenic [[purpura]], and [[thrombocytopenic purpura]].
 
'''Hypersensitive Reactions''': [[Fever]] combined with [[aching]] and [[sore throat]], [[laryngospasm]] and [[respiratory distress]].
 
===Postmarketing Experience===
 
The following adverse reactions have been reported during postapproval use of Lopressor: [[confusion|confusional state]], an increase in blood [[triglycerides]] and a decrease in [[HDL|High Density Lipoprotein (HDL)]]. Because these reports are from a population of uncertain size and are subject to confounding factors, it is not possible to reliably estimate their frequency.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = LOPRESSOR (METOPROLOL TARTRATE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=bb05420c-fd24-4672-9f62-fdd313819287 | publisher =  | date =  | accessdate = }}</ref>
 
==References==
 
{{Reflist}}
 
{{FDA}}
 
[[Category:Beta blockers]]
[[Category:Cardiovascular Drugs]]
[[Category:Drugs]]

Latest revision as of 03:48, 22 July 2014